You are here: Home » 0 » » Archives for 0st

Nyxoah Files Shelf Registration Statement and Announces At-the-Market Equity Offering Program

INSIDE INFORMATION
REGULATED INFORMATION

Nyxoah Files Shelf Registration Statement and
Announces At–the–Market Equity Offering Program

Mont–Saint–Guibert, Belgium "" December 22, 2022, 10:10pm CET / 4:10pm ET "" Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it has filed a $200 million shelf registration statement on Form F–3 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC"). Once declared effective by the SEC, the Registration Statement would permit the Company to sell, from time to time, up to $200 million in aggregate value of its common stock, preferred stock, debt securities, warrants, and/or units. The Registration Statement is intended to provide the Company with flexibility to access additional capital when market conditions are appropriate.

The Company also entered into a sales agreement (the "Sales Agreement") with Cantor Fitzgerald & Co. ("Cantor"), as sales agent, pursuant to which the Company may sell new ordinary shares having an aggregate offering price of up to $50 million (the "Offered Shares") from time to time through an “at–the–market” offering (the "ATM"). The actual number of Offered Shares to be issued, if any, will depend on the Company's determination, in its sole discretion, to make sales and the price per share of any such sales. However, the number of Offered Shares shall not exceed 6 million shares. The Offered Shares will be sold at a sales price per Offered Share equal to the then current USD market price of the Nyxoah ordinary share on the Nasdaq Global Market at the time of the relevant sale.

Cantor may sell Offered Shares by any method permitted by law deemed to be an "at–the–market" offering as defined in Rule 415 of the Securities Act of 1933, as amended, including without limitation sales made directly on the Nasdaq Stock Market, on any other existing U.S. trading market for the ordinary shares, or to or through a market maker. Since the Offered Shares will be sold at market prices prevailing at the time of the sale, sales prices may vary. No sales of Offered Shares will be conducted in Belgium or through Euronext.

The ATM offering is being made only by means of a prospectus included within the Registration Statement. The Registration Statement has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the Registration Statement becomes effective. When available, copies of the prospectus relating to the ATM may be obtained from Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, New York, NY 10022, or by email: prospectus@cantor.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

Caution "" CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward–looking statements
Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company's current expectations regarding the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20–F for the year ended December 31, 2021, filed with the Securities and Exchange Commission ("SEC") on March 24, 2022, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward–looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward–looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494

Attachment


GLOBENEWSWIRE (Distribution ID 1000773914)

Quantexa Positioned by Global Risk Analyst Firm Chartis as a Category Leader in 2023 RiskTech 100 Report for Trade-Based Money Laundering Solutions

LONDON, Dec. 22, 2022 (GLOBE NEWSWIRE) — Today Quantexa, a global leader in Decision Intelligence (DI) solutions for the public and private sectors, announced that their Decision Intelligence Platform has been recognized as a category leader in the Chartis RiskTech100 report for Trade–Based Anti–Money Laundering Solutions (TBAML). Quantexa's Decision Intelligence Platform has also been recognized by Chartis as a category leader in the recently released Chartis Financial Crime Risk Management Systems, Entity Management and Analytics Quadrant report.

RiskTech 100: Trade–Based Anti–Money Laundering Solutions
The 2023 RiskTech100 report ranks the world's major players in risk and compliance technology. In the Trade–based money laundering (TBML) category Quantexa was named as a category leader for data support of their enterprise solution. The Quantexa Trade AML Solution was also ranked for depth of typology coverage, breadth of analytical techniques and workflow.

Today's Anti–money laundering efforts face many growing and unresolved challenges. In a digital and globalized world, criminals are using a wide range of strategies to be successful "" making context a critical factor in the ability to accurately detect trade–based money laundering. By unifying internal and external data sources and scaling to understand billions of transactions, Quantexa's Decision Intelligence Platform helps organizations create a holistic view of transactional, customer, and counterparty information. Quantexa's approach to TBAML provides more accurate and efficient detection so organizations can reduce risk, assure compliance, and protect their reputation. Increased alert quality and automation, combined with reducing the volume of false positives helps organizations gain efficiencies and do more with the resources they already have.

Financial Crime Risk Management Systems: Entity Resolution
Quantexa's dynamic Entity Resolution Solution capability that is a critical part of its industry leading Decision Intelligence Platform was recognized for coverage, scalability, data enrichment, depth and breadth of data sources supported.

Quantexa's Entity Resolution Solution is an advanced data matching capability that connects disparate and ambiguous internal and external data at scale. Entity Resolution creates focused and complete views of people, organizations, places, and other data delivering game changing data quality and match rate accuracy. Quantexa also supports "dynamic entity resolution', which gives unique flexibility across multiple use cases and informs granular and extensive security protocols.

Decision Intelligence Platform
Quantexa's Decision Intelligence Platform gives enterprises the ability to unify their data by connecting siloed sources and systems, providing the context needed to visualize the complex relationships that enable previously hidden risk to be discovered. Quantexa's unique entity resolution technology can connect the most disparate and ambiguous internal and external data at scale to create single, complete views of people, organizations, places, and other data with 99% accuracy, handling poor quality data with exceptional performance. The result is a single view of data that becomes their most trusted and reusable resource across the organization.

Chartis Chief Researcher Sidhartha Dash said:

"Quantexa's increasingly mature solutions and their strong implementations in large financial institutions leveraging network–based concepts, drove their rise in the RiskTech 100 as well as their leadership in TBAML and Entity Management quadrants."

Quantexa Chief Product Officer Dan Higgins added:

"Quantexa is delighted to be included in the RiskTech 100 report, positioned very strongly amongst an esteemed list of enterprise solution providers. At Quantexa, we are keenly aware that criminals are hiding in plain sight and that traditional monitoring systems and manual controls just can't handle today's complexity, scale of activity and the underlying regulatory shifts, in particular the focus on counterparty risk, as well as customers. The usage of contextual monitoring to detect and manage the holistic financial crime and fraud risks within International Trade, including the identification of prerequisites such as underlying collusion, the presence of shell companies and professional money laundering gatekeeps and enablers has been a defining factor in Quantexa's success in this space."

ABOUT QUANTEXA

Quantexa is a global data and analytics software company pioneering Contextual Decision Intelligence that empowers organizations to make trusted operational decisions by making data meaningful. Using the latest advancements in big data and AI, Quantexa's platform uncovers hidden risk and new opportunities by providing a contextual, connected view of internal and external data in a single place. It solves major challenges across data management, KYC, customer intelligence, financial crime, risk, fraud, and security, throughout the customer lifecycle.

The Quantexa Decision Intelligence Platform enhances operational performance with over 90% more accuracy and 60 times faster analytical model resolution than traditional approaches. Founded in 2016, Quantexa now has more than 500 employees and thousands of users working with billions of transactions and data points across the world. The company has offices in London, New York, Boston, Washington DC, Brussels, Toronto, Singapore, Melbourne, and Sydney. For more information, contact Quantexa here or follow us on LinkedIn.

ABOUT CHARTIS

Chartis is a research and advisory firm that provides technology and business advice to the global risk management industry. Chartis provides independent market intelligence regarding market dynamics, regulatory trends, technology trends, best practices, competitive landscapes, market sizes, expenditure priorities, and mergers and acquisitions. Chartis' RiskTech Quadrant reports are written by experienced analysts with hands–on experience of selecting, developing, and implementing risk management systems for a variety of international companies in a range of industries, including banking, insurance, capital markets, energy, and the public sector.

Media Inquiries:

C: Laurel Case, VP, Fight or Flight

T: +1 315 663 6780

E: Quantexa@fightflight.co.uk

C: Adam Jaffe, SVP of Corporate Marketing
T: +1 609 502 6889
E: adamjaffe@quantexa.com
"" or ""
RapidResponse@quantexa.com


GLOBENEWSWIRE (Distribution ID 1000773686)